Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

South San Francisco, Calif.-based biotechnology firm launches PhenoSense GT HIV drug resistance test Nov. 15. The test, which integrates ViroLogic's phenotypic assay PhenoSense HIV with the firm's genotypic assay GeneSeq HIV, is the "first HIV drug resistance test to provide doctors with a single report on a patient's drug resistance profile using phenotypic test results supplemented by genotypic information," according to the firm...

You may also be interested in...

ViroLogic Vying For HIV Resistance Market Advantage As Rival Mulls Merger

ViroLogic's new HIV replication assay will help drive conversion of the resistance testing market from genotype to phenotype-based tests, the firm believes

Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53

The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.

UK Set For January Brexit After Conservatives Win Election

The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts